IOVA vs VRTX
Iovance Biotherapeutics, Inc. vs Vertex Pharmaceuticals — AI-powered side-by-side comparison
IOVA
Iovance Biotherapeutics, Inc.
67
Buy
VS
VRTX
Vertex Pharmaceuticals
66
Buy
| Metric | IOVA | VRTX |
|---|
| AI Score |
67
|
66
|
| Price |
$6.49
|
$529.70
|
| P/E Ratio |
-9.27×
|
30.58×
|
| ROE |
-56.0%
|
21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
116.3%
|
86.0%
|
| Debt / Equity |
0.06×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
79.2
|
80.4
|
| Beta |
0.701
|
0.305
|
| Expected Upside |
—
|
+1.5%
|
AI Committee View
Current Innellis committee reasoning for IOVA versus VRTX.
IOVA leads by 1 points.
IOVA scores 67/100 (Buy) versus VRTX at 66/100 (Buy).
IOVA Committee View
67% agreement
6 analysts
The primary driver is revenue growing 34.5% yoy -- genuine top-line momentum. The main limiting factor is roe of only -40.5% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- RSI at 79 is in overbought territory — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
VRTX Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 23.3% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 29.0 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- RSI at 80 is in overbought territory — Technical